NHMRC funding success

Tuesday, 18 November 2014


Professor Phil Hansbro and his team have been awarded over $1 million from the NHMRC to investigate modifying epigenetics as a novel treatment in COPD.

Modifying epigenetics as a novel treatment in COPD

Chronic obstructive pulmonary disease (COPD) is a term used to describe a number of lung conditions that are long-term, gradually worsen, and cause shortness of breath by reducing the normal flow of air through the airways.  This debilitating and life-threatening disease commonly appears worldwide as emphysema, chronic bronchitis and chronic asthma. Cigarette smoking induces chronic inflammation, which leads to progressive airway remodelling and the destruction of alveolar tissue. These events induce declining lung function, worsening breathlessness and COPD. Current therapies suppress the symptoms, but there are no treatments that halt the progression of disease.

Find out more